Abstract
Over the past several decades the important progress has been made in the management of acute lymphoblastic leukemia (ALL), especially among children. However, in adult patients reported cure rates seldom exceeded 40%, despite the use of hematopoietic stem-cell transplantation in many cases. Conventional chemotherapy is toxic and ineffective. Therefore, new treatment options and risk-adapted therapies are needed to improve the outcome of ALL patients. This review is focused on new systemic treatment modalities, such as nucleoside analogues, purine synthetase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors and other agents targeting molecular pathways that are aimed to benefit patients and improve the outcome of their treatment.
Keywords: Acute lymphoblastic leukemia, blinatumomab, DOT1L inhibitors, JAK/STAT inhibitors, monoclonal antibodies, mTOR inhibitors, NOTCH inhibitors, nucleoside analogues, tyrosine kinase inhibitors
Current Cancer Drug Targets
Title:Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Volume: 12 Issue: 5
Author(s): E. Lech-Maranda and W. Mlynarski
Affiliation:
Keywords: Acute lymphoblastic leukemia, blinatumomab, DOT1L inhibitors, JAK/STAT inhibitors, monoclonal antibodies, mTOR inhibitors, NOTCH inhibitors, nucleoside analogues, tyrosine kinase inhibitors
Abstract: Over the past several decades the important progress has been made in the management of acute lymphoblastic leukemia (ALL), especially among children. However, in adult patients reported cure rates seldom exceeded 40%, despite the use of hematopoietic stem-cell transplantation in many cases. Conventional chemotherapy is toxic and ineffective. Therefore, new treatment options and risk-adapted therapies are needed to improve the outcome of ALL patients. This review is focused on new systemic treatment modalities, such as nucleoside analogues, purine synthetase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors and other agents targeting molecular pathways that are aimed to benefit patients and improve the outcome of their treatment.
Export Options
About this article
Cite this article as:
Lech-Maranda E. and Mlynarski W., Novel and Emerging Drugs for Acute Lymphoblastic Leukemia, Current Cancer Drug Targets 2012; 12 (5) . https://dx.doi.org/10.2174/156800912800673275
DOI https://dx.doi.org/10.2174/156800912800673275 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Editorial (Thematic Issue: New Therapeutic Approaches for the Treatment of Glioblastoma)
Current Cancer Drug Targets Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Glioblastoma Multiforme Imaging: The Role of Nuclear Medicine
Current Radiopharmaceuticals Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design
Anti-Cancer Agents in Medicinal Chemistry Unsupervised End-to-End Brain Tumor Magnetic Resonance Image Registration Using RBCNN: Rigid Transformation, B-Spline Transformation and Convolutional Neural Network
Current Medical Imaging Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design